Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Discovery of a plasma signature of fronto-temporal degeneration and amyotrophic lateral sclerosis linked to a mutation of the C9orf72 gene

Published on: 04/12/2020 Reading time: 1 min
schéma

A joint study by teams from the Paris Brain Institute at the Pitié-Salpêtrière hospital and from Inria (Rennes and Paris centers) has revealed for the first-time plasma microRNA signatures in individuals with or presymptomatic of fronto-temporal degeneration or amyotrophic lateral sclerosis. The discovery of this potential new biomarker, published in the Journal of Neurology, Neurosurgery and Psychiatry, represents an important step forward in assessing the clinical progression of patients and the efficacy of future treatment candidates in therapeutic trials.

Frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative diseases that may have a common genetic cause, the most common of which is a mutation in the c9orf72 gene. DFTs cause behavioural, language, and emotional control disorders and affect cognitive, reasoning, and judgment abilities. ALS, on the other hand, is a disease of the motor neurons leading to muscle weakness and progressive paralysis.

At present, there is no treatment for these two pathologies. The identification of specific markers of the progression of these pathologies is essential in order to best adapt patient management and evaluate the efficacy of treatment in clinical trials. To this end, the PREV-DEMALS* study, coordinated by Dr. Isabelle Le Ber, is following 22 patients with the c9orf72 mutation, 45 presymptomatic individuals with the mutation and 43 control subjects.

A specificity of these pathologies associated with the c9orf72 mutation is the presence of pathological inclusions consisting of the TDP-43 protein in the brain of patients. TDP-43 plays an important role in the formation of microRNAs (miRNAs), small fragments of genetic material that regulate gene expression. Could the formation of these inclusions in patients' brains have an effect on miRNA synthesis?

The association of these miRNAs with many neurodegenerative diseases is increasingly suspected. The possibility of measuring their presence in blood plasma makes them all the more interesting as potential biomarkers of the evolution of these diseases.

A collaborative study** conducted by the teams of Isabelle Le Ber (AP-HP) and Olivier Colliot (CNRS, joint team with Inria Paris) at the Paris Brain Institute (Inserm/CNRS/Sorbonne University) and with Emmanuelle Becker at Inria Rennes (IRISA, Dyliss team), as part of Virgilio Kmetzsch's thesis work, focused on miRNAs present in the plasma of subjects in the PREV-DEMALS cohort.

The researchers identified 4 miRNAs expressed differently between patients and control subjects. Two were over-expressed in patients, while two were under-expressed. One of the two over-expressed miRNAs, MiR-34a-5p, was also over-expressed in presymptomatic subjects, suggesting deregulation of this miRNA associated with the c9orf72 mutation. The second, miR-345-5p, was more expressed in patients compared to presymptomatic subjects, suggesting a correlation between disease progression and increased miRNA expression. The two under-expressed miRNAs were, however, associated with an already fully established pathology. In addition, 4 presymptomatic individuals near the clinical onset of the disease had miRNA expression levels very similar to those of the patients, also showing the value of this signature in determining the timing of clinical conversion.

Taken together, these results highlight for the first time a miRNA transcriptomic signature specific to the presymptomatic and symptomatic stage of FTD/ALS associated with a mutation in the C9orf72 gene. This signature could constitute an important biomarker in these diseases, in particular in the transition to the clinical phase. It could also be used for the initiation and monitoring of therapies administered at an early stage, as early as the presymptomatic phase.

* The PREV-DEMALS cohort is funded by ANR/DGOS PRTS and under AP-HP promotion. Patient follow-up is carried out at the Institute of Memory and Alzheimer's Disease at the Pitié-Salpêtrière Hospital AP-HP and at the Clinical Investigation Center at the Paris Brain Institute.

** This research is conducted as part of the IPL Neuromarkers project, a large-scale collaboration between Inria and the Paris Brain Institute, whose objective is to develop new computational and statistical approaches for the prediction and study of the evolution of neurodegenerative diseases.

Sources

https://jnnp.bmj.com/content/92/5/485
Kmetzsch V. et al. Journal of Neurology, Neurosurgery and Psychiatry. 2020

Our news on the subject

Le développement du cerveau a une part d’aléatoire
The stochastic aspect of brain development
Although every person’s personality is the result of genetic and environmental factors, these are not the only factors at play. Bassem Hassan and his team at Paris Brain Institute have discovered that, in fruit flies (drosophila), individuality also...
05.12.2025 Research, science & health
Analyse MERSCOPE
New treatment pathways for brain malformation-linked focal epilepsy?
A study by Stéphanie Baulac’s team has revealed somatic mutations in different cell types in patients with type 2 focal cortical dysplasia. This disease causes drug-resistant epileptic seizures, for which the main treatment option is currently...
05.12.2025 Research, science & health
Un iceberg
The ICEBERG cohort, 10 years of collective scientific and medical mobilization
The ICEBERG cohort, initiated 10 years ago, is interested in studying factors predictive of the onset and progression of Parkinson’s disease.
05.15.2025 Research, science & health
La huntingtine est une protéine indispensable au développement embryonnaire, à la formation et au maintien du tissu cérébral.
Huntington's Disease: The Energy Hypothesis Gets Traction
Huntington's disease, a rare hereditary neurological disorder, is associated with an energy deficit that precedes the onset of symptoms and is closely linked to their progression. At Paris Brain Institute, Fanny Mochel and her colleagues are testing...
02.11.2025 Research, science & health
À la recherche de marqueurs d’imagerie dans la démence frontotemporale
Searching for Imaging Markers in Frontotemporal Dementia
Could exploring the relationships between different brain networks help us understand frontotemporal dementia (FTD)? This neurodegenerative disease, which progresses at varying rates, is often diagnosed late—when clinical signs are already severe. At...
01.07.2025 Research, science & health
Monocyte – un globule blanc qui se différencie en macrophage. Crédit : Université d’Edinbourg.
Discovery of a Macrophage Anomaly in Multiple Sclerosis
Certain patients with multiple sclerosis (MS) can partially regenerate myelin—the protective sheath that surrounds nerve fibers—which is damaged during the evolution of the disease. In studying how immune cells influence this remyelination...
12.19.2024 Research, science & health
See all our news